Bassil Dahiyat has been Xencor’s president and chief executive officer since the Company’s incorporation in August 1997. He is the co-founder of Xencor and co-inventor of Xencor’s breakthrough XmAb^® technology. He has led the Company in creating a diverse clinical-stage portfolio of engineered antibodies and cytokines for the treatment of life-threatening and debilitating diseases, and has established alliances with leading biopharmaceutical companies that have resulted in three marketed drugs. Dr. Dahiyat has co-authored numerous scientific papers in the fields of protein design and drug delivery, is an inventor of over 30 U.S. and numerous foreign patents and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society and Caltech. Dr. Dahiyat also serves as a member of the board of directors of Kodiak Sciences and Terray Therapeutics. He holds a Ph.D. in Chemistry from Caltech and B.S. and M.S.E. degrees in Biomedical Engineering from the Johns Hopkins University.

Dr. Desjarlais oversees all aspects of discovery and research at the company, including technology development, protein and antibody engineering and generation of drug candidates, and has served as chief scientific officer since 2014. Before joining Xencor in 2001, Dr. Desjarlais was an Assistant Professor of Chemistry at Penn State University, where he developed protein engineering methods. He then conducted postdoctoral research at the University of California, Berkeley. Dr. Desjarlais received a B.S. in physics from the University of Massachusetts and a Ph.D. in biophysics from Johns Hopkins University. He completed a post-doctoral fellowship at the University of California, Berkeley.

Dr. Valente is responsible for leading Xencor’s clinical and medical strategy and execution. Before Xencor, she most recently served as a senior vice president at Genentech, a member of the Roche Group, and as its global head and co-lead of global product development of its oncology and hematology therapeutic area. In this role at Genentech, Dr. Valente was responsible for strategic planning, clinical development and collaboration activities in the areas of oncology and hematology product development, playing a critical role in the development and approvals of new therapies for patients with serious illnesses, including GAZYVA^®, VENCLEXTA^®, POLIVY^® and HEMLIBRA^®. Dr. Valente has held various positions with increasing responsibilities at Genentech and then at Roche after Genentech was acquired by Roche, including vice president for global product development for oncology, hematology franchise and senior group medical director, leader for hematology development. Before Genentech, she served in senior-level positions at Anosys, Inc. and Coulter Pharmaceutical, Inc., and earlier in her career, she held academic positions at the University of California, San Francisco (UCSF). Dr. Valente received her M.D. from the University of Missouri and completed her internal medicine training at Oregon Health & Science University, followed by fellowships in hematology at Stanford University and oncology at UCSF.

Mr. Cornelissen brings more than 20 years of experience in corporate financial planning, analysis and transactions to Xencor, where he has primary responsibility for financial reporting, budgeting, cash-flow management, investments, information technology and facilities. Before Xencor, Mr. Cornelissen was vice president, corporate finance at Seagen Inc., where he built and scaled the corporate finance organization to support tremendous revenue growth and dealmaking activity, including the company’s $43 billion acquisition by Pfizer in 2023. Before Seagen, while at the Bill & Melinda Gates Foundation, he served as vice president, finance for the END Fund and as finance lead for malaria and neglected tropical disease initiatives. Earlier in his career, Mr. Cornelissen led multiple finance teams at DSM Nutritional Products, a former division of Roche. He began his career in life sciences and health within global financial planning and analysis at Novartis. Mr. Cornelissen received his M.Sc. in Business Administration from the Rotterdam School of Management at Erasmus University.

Ms. Eckert joined Xencor as vice president, general counsel and corporate secretary in September 2019. Previously, she served as vice president, corporate legal at Synthetic Genomics. In that role, she negotiated licensing and financial transactions and supported other corporate legal matters. Before Synthetic Genomics, Ms. Eckert served as associate general counsel at Sequenom and as senior director, legal affairs at Prometheus Laboratories. At Prometheus, she structured transactions, managed substantial patent litigation and supported the growth of the company’s commercial organization. Earlier in her career, she was an associate at Jones Day and at Pillsbury Winthrop Shaw Pittman LLP. Ms. Eckert earned a B.A. in political science from the University of California, Los Angeles, and a J.D. from the University of California, College of the Law, San Francisco.

Dr. Grunstein brings more than 20 years of expertise in partnering, acquisitions and licensing in the biopharmaceutical industry and will lead strategic partnering to enhance the development of Xencor’s pipeline of drug candidates. Dr. Grunstein joins Xencor from Amgen, where he served in several strategic business development roles. Most recently, he served as executive director, transactions, where he led product and platform technology transactions and managed Amgen’s out-licensing and corporate equity portfolio. Before joining Amgen, Dr. Grunstein earned an MBA from the Sloan School of Management at the Massachusetts Institute of Technology and completed a post-doctoral fellowship in the Department of Molecular Oncology at Genentech. He earned a Ph.D. in biology from the University of California, San Diego, and a B.S. in biology from the University of California, Los Angeles.

Mr. Kowack oversees all aspects of the program leadership and strategic alliances group in support of Xencor’s internal and external portfolios. Previously, he served as vice president of program leadership and precision medicine at Ignyta, where he led early-stage development programs while spearheading Ignyta’s contributions to the Cancer Moonshot initiative. Mr. Kowack has extensive experience leading oncology-focused drug development teams at Pfizer, where he served as asset team leader for 19 different programs, including Ibrance^® (palbociclib) from Ph 1b to approval. Mr. Kowack served in the United States Coast Guard in several roles of increasing responsibility, including Commanding Officer of a cutter, before retiring as a Commander in the USCGR. He earned an M.S. in biochemistry from Dartmouth College and an MBA from Marist.

Mr. Leone brings 20 years of experience as a leading equity research analyst to Xencor, where he supports the Company’s R&D leadership to enhance value across Xencor’s platform technologies by overseeing assessment and prioritization of Xencor’s current and future XmAb® drug candidates. Mr. Leone most recently served as a managing director and senior biotechnology analyst at Raymond James. Mr. Leone’s focus areas in equity research included oncology, immunology, cardiology and ophthalmology. His coverage spanned securities across a wide range of market capitalization, from biotechnology companies advancing a diverse set of drug candidates to commercializing novel medicines. Before Raymond James, Mr. Leone held analyst roles with increasing seniority at BTIG and Macquarie Securities Group. He began his career in portfolio management as a health care and quantitative research analyst at AllianceBernstein. Mr. Leone received his B.S. in business from the State University of New York at Albany. He holds the Chartered Financial Analyst® designation from the CFA® Institute.

CFA® and Chartered Financial Analyst® are registered trademarks of CFA Institute.

Mr. Rosemark brings to Xencor over 25 years of biopharmaceutical industry experience, leading regulatory affairs and quality assurance organizations, developing and registering products with regulatory authorities and supporting them throughout their lifecycles. Before joining Xencor, he most recently served as vice president, regulatory affairs at Beigene (USA), where he developed and evaluated regulatory approval strategies for multiple development projects and combinations thereof and held responsibility for 14 INDs. Before Beigene, Mr. Rosemark was vice president, regulatory affairs and quality assurance at CymaBay Therapeutics, where he led the regulatory strategies for several mid-to-late stage programs, several of which with preferential designations with health authorities. From 2003 to 2014, he was vice president, regulatory affairs and quality assurance at Exelixis, where he led to the regulatory team on the Cometriq^® program, taking it from discovery through approvals in the U.S. and EU. Earlier in his career he held roles of increasing responsibility in regulatory affairs at Solvay Pharmaceuticals, Ciba Vision and Bausch & Lomb Pharmaceuticals. Mr. Rosemark received a B.S. in chemistry from Cleveland State University.

Ms. Sandoz brings 25 years of wide-ranging healthcare experience to Xencor, where she is responsible for leading Xencor’s overall human resources strategy. Ms. Sandoz previously served as Vice President, Human Resources at Surgical Care Affiliates, an OptumCare company, where she led teams in talent acquisition, compensation, and learning & organizational development. Before Surgical Care Affiliates, she held progressively more senior roles in human resources at Amgen, following a role as a program manager on their first oncology BLA submission, for Vectibix^® (panitumumab). Earlier in her career, she worked in management consulting at Deloitte and in clinical research at Parke-Davis (now Pfizer). Ms. Sandoz received a B.S. in nursing from the University of Pennsylvania and an M.S. in nursing from the University of Michigan.